Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2013

SPEE3D PARTNERS WITH MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY TO BRING METAL ADDITIVE MANUFACTURING TECHNOLOGY TO COMMUNITY

Retrieved on:

Wednesday, July 19, 2023

Workforce, Missouri University of Science and Technology, Partnership, Printing, 3D, Forging, Research, S&T, Student, Entrepreneurship, Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2013, 3D printing

Melbourne, Australia, July 19, 2023 (GLOBE NEWSWIRE) -- SPEE3D , a leading metal additive manufacturing company, announced they have partnered with Missouri University of Science and Technology (S&T) to bring their metal additive manufacturing technology to the school’s Kummer Institute Center for Advanced Manufacturing.

Key Points:

Melbourne, Australia, July 19, 2023 (GLOBE NEWSWIRE) -- SPEE3D , a leading metal additive manufacturing company, announced they have partnered with Missouri University of Science and Technology (S&T) to bring their metal additive manufacturing technology to the school’s Kummer Institute Center for Advanced Manufacturing.
The school has purchased the WarpSPEE3D printer to address research manufacturing and industry supply chain needs, such as replacing castings and forgings.
WarpSPEE3D is the world’s first large-format metal 3D printer to use patented SPEE3D technology that enables significantly faster and more scalable production than traditional manufacturing.
This tremendous speed transforms metal 3D printing from being useful for prototyping or low-volume production into a real-world manufacturing solution.

Tampa General Hospital Named to Becker's Hospital Review 'Great Hospitals in America' List

Retrieved on:

Friday, June 30, 2023

TAMPA, Fla., June 30, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the greatest hospitals in the U.S., according to the 2023 Becker's Hospital Review "Great Hospitals in America" list.

Key Points:

Tampa General is recognized as a national leader and the only hospital in the Tampa Bay region recognized for clinical excellence and leadership.
TAMPA, Fla., June 30, 2023 /PRNewswire/ -- Tampa General Hospital (TGH) has been named one of the greatest hospitals in the U.S., according to the 2023 Becker's Hospital Review "Great Hospitals in America" list.
Tampa General is one of 86 hospitals nationwide, one of only two hospitals in Florida and the only hospital in the Tampa Bay region to receive recognition on Becker's list.
Inclusion on the Becker's "Great Hospitals in America" list is the latest among several high-profile recognitions for Tampa General Hospital, including:

Reliant Powers Statewide Summer Support

Retrieved on:

Monday, June 12, 2023

This summer, Reliant has committed $1 million to CARE funding in direct support of customers across Texas.

Key Points:

This summer, Reliant has committed $1 million to CARE funding in direct support of customers across Texas.
Contact 24/7 Customer Support: Reliant prioritizes giving everyone access to the electricity they need to live comfortably.
Anyone shopping for a new electricity plan, concerned about summer bills, or needing payment assistance is encouraged to contact Reliant.
Agents are available 24/7 via live phone support, online chat, or on the Reliant app.

Folio Photonics Expands Engineering Leadership Team with the Appointment of Greg Kittilson as Vice President of Engineering

Retrieved on:

Tuesday, February 7, 2023

Folio Photonics today announced the appointment of industry veteran Greg Kittilson as Vice President of Engineering.

Key Points:

Folio Photonics today announced the appointment of industry veteran Greg Kittilson as Vice President of Engineering.
In this position, Kittilson will lead the engineering team in developing and delivering the first-ever enterprise-scale, immutable active archive solution, that provides breakthrough cost, margin, and sustainability benefits to the market.
He will act directly under the CEO, Steve Santamaria, and work across functional teams to further the product development process.
“This patent plays a key role in enabling Folio Photonics' optical media to be used for data storage,” said Steve Santamaria, Folio Photonics.

Aclarity Destroys PFAS Chemicals Forever in Full-Scale Pilot

Retrieved on:

Wednesday, January 11, 2023

BOSTON, Jan. 11, 2023 /PRNewswire/ -- Aclarity, a leading PFAS destruction technology company, announced today that it has successfully destroyed PFAS chemicals at a customer's site, at volume, in landfill leachate, a primary source of PFAS contamination in the environment.

Key Points:

Existing methods for managing PFAS in landfill leachate merely shift PFAS chemicals within our environment.
BOSTON, Jan. 11, 2023 /PRNewswire/ -- Aclarity , a leading PFAS destruction technology company, announced today that it has successfully destroyed PFAS chemicals at a customer's site, at volume, in landfill leachate, a primary source of PFAS contamination in the environment.
The full-scale pilot , sponsored by Xylem , a leading water technology company, demonstrates that PFAS, otherwise known as "forever chemicals," a class of highly toxic and ubiquitous substances previously resistant to any form of degradation, can be destroyed at full-scale capacity for large operations.
"Existing methods for managing PFAS in landfill leachate merely transfer the chemicals within our environment," Julie Bliss Mullen, Aclarity CEO, said.

DiNAQOR Appoints Two Seasoned Executives to Leadership Team

Retrieved on:

Monday, January 9, 2023

SCHLIEREN, Switzerland, Jan. 9, 2023 /PRNewswire/ -- DiNAQOR, a genetic medicine platform company, today announced that it has added to its leadership team with the appointments of two veteran biotechnology executives. Chris Rusconi, Ph.D., who brings decades of experience in global pharmaceutical development, will serve as DiNAQOR's Chief Development Officer. Steven Zelenkofske, D.O., M.S., an expert in clinical development and adaptive trial design and operations who serves on DiNAQOR's board of directors, will assume the role of Chief Strategy Officer.

Key Points:

Chris Rusconi to serve as Chief Development Officer; Steven Zelenkofske to take role of Chief Strategy Officer as DiNAQOR continues rapid growth
SCHLIEREN, Switzerland, Jan. 9, 2023 /PRNewswire/ -- DiNAQOR , a genetic medicine platform company, today announced that it has added to its leadership team with the appointments of two veteran biotechnology executives.
Chris Rusconi, Ph.D. , who brings decades of experience in global pharmaceutical development, will serve as DiNAQOR's Chief Development Officer.
"We are fortunate to add Chris and Steve's expertise to DiNAQOR's leadership at such a pivotal time for our company," said Johannes Holzmeister, M.D., Chairman and CEO of DiNAQOR.
"Taking on a leadership role with DiNAQOR is an exciting opportunity and the beginning of a new chapter for me," Dr. Rusconi said.

Institute for Bioscience and Biotechnology Research Awarded $6.9M to Design and Test a Vaccine to Combat Hepatitis C

Retrieved on:

Monday, August 22, 2022

Princeton University, Liver cancer, Molecular biology, University, Public health, Research, National Institute, Cirrhosis, National Institute of Standards and Technology, Virginia BioTechnology Research Park, UMCP, NIST, Engineering, Maryland School, Associate, HCV, Disease, Solution, UMB, College Park, Hepatocellular carcinoma, Senior, Department, Science, Biomedical Research, School, Infection, Cell biology, Faculty, Liver disease, State, Fibrosis, Biotechnology, Assistant, NIAID, History of the University of Maryland, College Park, Paul D. Wellstone Muscular Dystrophy Community Assistance, Research and Education Amendments of 2013, Institute, Hepatitis C, Assistant professor, List of life sciences, National Institute of Allergy and Infectious Diseases, University of Maryland School of Medicine, Pharmaceutical industry, Technology, Microbiology

Hepatitis C Virus (HCV) puts people at heightened risk for severe liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma (liver cancer).

Key Points:

Hepatitis C Virus (HCV) puts people at heightened risk for severe liver disease, including fibrosis, cirrhosis, and hepatocellular carcinoma (liver cancer).
Although treatments are available, an HCV vaccine currently does not exist to help prevent infections and reduce the global burden of the disease.
The researchers aim to design a vaccine to induce broadly neutralizing antibodies and long-term memory T cell responses that will help prevent HCV infection.
Eric Toth, IBBR Fellow and Assistant Research Professor also serves as a co-Investigator and Yunus Abdul, IBBR Research Scientist will assist with animal studies.

NCPDP Foundation Awards Grant to University of Arizona R. Ken Coit College of Pharmacy to Identify Barriers to Using Indication/Diagnosis Fields in NCPDP Standards

Retrieved on:

Monday, June 27, 2022

SCOTTSDALE, Ariz., June 27, 2022 /PRNewswire-PRWeb/ -- The NCPDP Foundation Board of Trustees announced it has awarded a $60,000 grant to the University of Arizona R. Ken Coit College of Pharmacy to research and identify barriers to using the clinical indication (SNOMED CT) or diagnosis (ICD-10) fields in NCPDP's SCRIPT and Telecommunication Standards, which can aid pharmacists in drug utilization review, and improve patient care and patient safety. Pharmacy associations and medication safety organizations have long advocated for use of clinical indication or diagnosis on medication orders, and NCPDP strongly recommends use of the fields in all prescriptions. Use of the fields also supports pharmacists in providing prospective and retrospective drug utilization review (DUR) mandated by the Omnibus Budget Reconciliation Act of 1990 (OBRA 90) as well as laws or regulations enacted at the state level. The research project will produce a prioritized needs assessment to guide the action steps toward addressing and overcoming perceived barriers and concerns related to the routine exchange of clinical indication or diagnosis between prescribers and pharmacies in the ambulatory care setting.

Key Points:

Pharmacy associations and medication safety organizations have long advocated for use of clinical indication or diagnosis on medication orders, and NCPDP strongly recommends use of the fields in all prescriptions.
The NCPDP Foundation grant to the University of Arizona R. Ken Coit College of Pharmacy was made possible by the Mary and Charles D. Pulido Endowment Fund as granted to the NCPDP Foundation by the NCPDP Board of Trustees.
The NCPDP Foundation is a 501(c)(3) nonprofit charitable organization headquartered in Scottsdale, Arizona and is affiliated with the National Council for Prescription Drug Programs (NCPDP).
The NCPDP Foundation was established in December 2012 to support research, education, and charitable involvement within the healthcare industry.

HOOKIPA Announces Executive Leadership Changes

Retrieved on:

Tuesday, June 21, 2022

NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs.

Key Points:

NEW YORK and VIENNA, Austria, June 21, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, HOOKIPA), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced several leadership changes as the company expands its clinical development and pipeline programs.
In her new role, Schlienger becomes a member of the Executive Team and will lead all clinical development programs for HOOKIPA globally, inclusive of immuno- oncology and infectious diseases.
Prior to joining HOOKIPA, Necina was Senior Vice President and Chief Strategist at Takeda and a member of the companys R&D Pharmaceutical Science Leadership Team.
In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.

Reliant Supports Texans as Summer Heat Kicks In

Retrieved on:

Thursday, June 16, 2022

The summer of 2022 is shaping up to be one for the record books with extreme heat and double-digit inflation.

Key Points:

The summer of 2022 is shaping up to be one for the record books with extreme heat and double-digit inflation.
Community Assistance by Reliant Energy (CARE): The CARE program helps customers who are facing financial hardship pay their electricity bills through local agency assistance, made possible by both Reliant and customer contributions.
This summer, Reliant is increasing its CARE funding commitment to $1 million to directly support customers across Texas.
For more information about Reliant, visit reliant.com and connect with Reliant on Facebook at facebook.com/reliantenergy and Twitter or Instagram @reliantenergy.